July 24, 2017 - New Products Announcement

New Purified and labeled monoclonal antibodies available to enhance immunophenotyping and immunomonitoring. 

Norcoss, Georgia (July 24, 2017)

 

Caprico Biotechnologies Inc (CBI) today announced the release of several new purified and labeled monoclonal antibodies validated for flow cytometry usage with immunophenotyping and immunomonitoring applications.   

 

The new products that available now either directly from CBI or via its global distribution network are:

  • Anti-human CD11b iFlour™ 647
  • Anti-human CD31 purified
  • Anti-human CD45RO purified
  • Anti-human CD68 purified
  • Anti-human CD81 APC
  • Anti-human CD81 PE
  • HLA-DR PE-Cyanine 7™
  • Anti-human Lambda Light chain purified
  • Anti-human IgG1,ĸ iFlour™ 488

 

“The release of these new antibodies further underlines CBI’s commitment to providing a comprehensive solution for researchers working in the immunephenotyping and immune-monitoring fields” said Dr Remus Li, MD, President and CEO. Dr Li added “CBI already provides over 500 different purified and labeled antibody combinations and we continue to expand our portfolio to ensure that high quality cost effective products are available.”

 

For more information, contact:

 

Punya Mardhanan:      Director of Marketing & Sales

Telephone                   +1 678-691-2143 ext 101

E-mail:                        p.mardhanan@capicobio.com

 

Caprico Biotechnolgies Inc (CBI) is a provider of products and services with flow cytometry applications. Core business activities include the production and supply of purified and labeled monoclonal antibodies for immunephenotyping and immunemonitoring and custom hybridoma development and labeling services. For more information about CBI visit their website at www.capricobio.com

 

Copyright © 2017 Caprico Biotechnologies Inc, All rights reserved